Kiyatec Inc. Receives Prestigious CAP Accreditation and New York State Approval for 3D Predict™
Kiyatec Inc., a leader in patient-specific cancer diagnostics, has announced its laboratory’s successful accreditation by the College of American Pathologists (CAP) and the receipt of New York State approval for its innovative 3D Predict™ test. These milestones highlight commitment to providing high-quality, personalized cancer diagnostics that improve patient outcomes.
CAP Accreditation: A Standard of Excellence
The CAP accreditation is widely recognized as the gold standard in laboratory quality assurance. It confirms that the laboratory operations meet the highest standards for accuracy, reliability, and excellence in diagnostic services. This accreditation serves as a testament to the company’s commitment to rigorous quality control processes and its mission to revolutionize cancer care through patient-specific solutions.
Along with the CAP accreditation, the laboratory is CLIA-certified (CLIA Certificate #42D2130169) and uses an Established CPT Code (0248U). These certifications further validate the clinical application and accessibility of it’s innovative diagnostic technology, underscoring the company’s role in advancing personalized oncology.
New York State Approval for 3D Predict™
Kiyatec has also received New York State approval for its 3D Predict™ tests, a significant achievement that demonstrates the clinical validity and utility of these assays. The 3D Predict™ platform utilizes live tumor cell analysis to forecast a patient’s response to cancer therapies. Kiyatec’s proprietary 3D cell culture technology is supported by published, peer-reviewed evidence, linking therapeutic response predictions to actual patient outcomes. This breakthrough sets a new benchmark in functional precision oncology, making it’s 3D Predict™ platform a critical tool for oncologists.
Advancing Treatment for High-Grade Gliomas
One of the key areas where Kiyatec’s 3D Predict™ platform is making a significant impact is in the treatment of high-grade gliomas, including glioblastoma. These aggressive cancers have seen minimal progress in therapeutic outcomes over the past several decades. With the 3D Predict™ Glioma test, it provides oncologists with actionable insights that guide treatment decisions, offering the first meaningful advancement in the management of these devastating cancers in years.
CEO Statement: A Step Closer to Personalized Cancer Care
Eric Perreault, CEO of Kiyatec, expressed his excitement about these accomplishments: “We’re thrilled to see our 3D Predict platform gaining this recognition. These approvals mean so much because they’re not just about validating our science – they’re about making a real difference in patients’ lives. I’m passionate about ensuring that more patients and their doctors have access to the personalized insights these tests provide, and this brings us one step closer to that goal.”
Personalized Cancer Diagnostics: The Future of Oncology
Kiyatec’s 3D Predict™ platform represents a paradigm shift in cancer diagnostics, moving away from the traditional one-size-fits-all approach to a more personalized treatment strategy. By accurately predicting how individual patients’ cancers will respond to specific therapies, empowers oncologists to make more informed, tailored decisions, leading to better outcomes and minimizing unnecessary side effects.
This innovative approach to cancer care is paving the way for a future where patients no longer have to rely on generalized treatment protocols but instead receive therapies that are customized to their unique tumor biology. As more patients gain access to Kiyatec’s 3D Predict™ tests, the potential for improved cancer treatment outcomes becomes even greater.
Conclusion: Kiyatec’s Impact on Cancer Care
With CAP accreditation, New York State approval, and a robust scientific platform, is setting the standard for personalized cancer diagnostics. Its 3D Predict™ tests are not only a breakthrough in precision oncology but also a critical step toward improving treatment outcomes for patients with difficult-to-treat cancers. Kiyatec’s commitment to quality, innovation, and patient-centric solutions continues to drive advancements in cancer care, offering hope to those affected by cancer.
About Kiyatec
Kiyatec is committed to advancing functional precision oncology with its proprietary 3D cell culture platform. By integrating science, technology, and clinical expertise, Kiyatec enables oncologists to deliver personalized cancer care that can improve patient outcomes. For more information, visit www.Kiyatec.com.
For more details about Kiyatec’s 3D Predict tests or to schedule an interview, please contact Eric Perreault at [email protected].
